From the day we’re born, our bodies contain a constant mix of chemicals. But our regulatory system only targets these substances one at a time. Current policies don’t adequately account for the health threats of mixtures, when two or more chemicals combine inside us.
In today’s episode, Ken talks about chemical mixtures with Dr. Jabeen Taiba, who recently published a study called, “Exploring the Joint Association Between Agrichemical Mixtures and Pediatric Cancer.”
From the study: “We observed a statistically significant positive association between 32 agrichemicals,” which were all pesticides, “and overall pediatric cancer and subtypes, and the strength of the association was slightly stronger among brain and CNS cancers compared to overall cancer.”
Taiba is a post-doctoral research associate at the University of Nebraska’s Water, Climate, and Health program. She’s trained as a multidisciplinary researcher, with a background in epidemiology, and has robust experience in clinical research, public health, and large data sets. She and Ken delve into what happens when chemicals mix and how this impacts our most vulnerable: children.
EWG has been studying mixtures since the early 2000s. But chemical companies only test one chemical at a time in its purest form. With more scientists like Taiba, we’re hopeful that can change.
Disclaimer: This transcript was compiled using software and may include typographical errors.
Ken Cook: So, Jabeen, I'm gonna start off with a couple of comments and then I'll just jump to you, and then later on we record a more formal introduction that will obviously extol your qualifications and your accomplishments, but I won't go through all of that now. I'll just start off.
Jabeen Taiba: Sure.
Jabeen Taiba: Good.
Jabeen Taiba: Sure.
Ken Cook: Hi, this is Ken Cook and I'm having another episode. I have them all the time. This one I'm especially excited about because I get to talk to a scientist early in her career, Jabeen Taiba, PhD. She's a postdoctoral research associate in the Water, Climate, and Health Program at the University of Nebraska.
She's a multidisciplinary researcher with a background in epidemiology, experience in clinical research, public health, and large data sets. And I'm really tickled to talk to Dr. Taiba today because the whole question of how we look at mixtures of chemicals and their impact on our health is central to what EWG's been talking about for years, and we've published a number of papers where we've taken an approach to try and understand this.
And the reason it's so important is because we are rarely exposed to one chemical at a time. And that's how they're evaluated in the regulatory system. It's one of the ways in which the regulatory system's pretty unrealistic when it comes to assessing how chemicals might be affecting our health.
And just to take it to a further degree, specifically, we don't test chemicals necessarily in the formulation they are in a product. We typically, in the case of pesticides, get what might be called reagent-grade versions of these chemicals that have no additives. And so if something is sprayed on a farm field, it often has many so-called inert ingredients in the formulation of the actual product.
And the same might be said of personal care products, food additives, and so forth. They are usually tested one at a time in their purest form, not as they're formulated in a product as you, as a human being, would experience it, or as it might show up in your blood.
And we have done tests over the years. We started in the early 2000s, and we found in umbilical cord blood hundreds of chemicals that the babies were exposed to. We know this happens, but we had really no understanding, and still don't really have much understanding, of what the effects might be of those mixtures.
We know—we found PCBs. We've got a lot of data on PCBs and their risk characterization. We found dioxins. We found certain PFAS. And for some of these, we have a pretty good, not always perfect, characterization of their hazardous properties. And from that, we can begin to infer what health effects they might be causing.
But in combination, you might have dozens of neurotoxins. Should you add them up? How should you think of dozens of carcinogens? How do they interact, or do they? Is separate consideration of each one the right way to go?
It doesn't feel scientific to me to do it that way, but that's the way we do it in our regulatory system. That's the expectation that companies have when they bring a chemical to the marketplace.
So today, I'm especially excited to talk to Dr. Jabeen Taiba about her study entitled "Exploring the Joint Association Between Agrochemical Mixtures and Pediatric Cancer."
Pediatric cancer—I mean, come on. I just—it just takes my breath away saying those words together. The notion of it is just horrifying. And so we know we have to take a close look at chemicals for that and other health outcomes.
But what Jabeen and her colleagues have done is they've looked at chemical mixtures. And I'm just gonna read one sentence from the abstract: "We observed a statistically significant positive association between 32 agrichemicals," and I think they were all pesticides, "and overall pediatric cancer and subtypes." And the strength of the association was slightly stronger among brain and CNS cancers compared to overall cancer.
And then this is—then I'll stop here and I'll turn and ask the expert, the scientist, the questions.
But three of my rogues' gallery of chemicals that EWG has worked on, trying to regulate them, encourage people to take them off the market in some cases or restrict them: dicamba, glyphosate, which is the active ingredient in Roundup formulations, Monsanto/Bayer, very controversial right now, and paraquat, which is also controversial.
We just had a barrel of paraquat fall off a truck in California and basically cause a small town to go into lockdown. It's so toxic and dangerous.
Dr. Taiba, thank you for joining. Tell me a little bit about your background, how you came to be interested in science, how you came to focus your scientific interest on this particular aspect of environmental health. And thanks again for joining.
So tell us, how did you get here? How did you get to be where you are now and doing such exciting work?
Jabeen Taiba: Thank you, Ken, first for having me here. Actually, I am by profession, I am a clinician. So I was a dentist back home in India. So that's where my science or biomedical background comes from. So I was always passionate about improving health. And that's what—from oral health to—that's what made me think on a broader scope of public health.
So I studied epidemiology, and while I was working at Cincinnati Children's Hospital as a clinical research coordinator, I had a broader exposure to different kinds of diseases and conditions. So cancer was always a priority to me, like prevention.
So I really had a wonderful opportunity to work on it when I was pursuing my PhD because I wanted to study further and one day be a PI and have my own lab. So that's my motivation behind pursuing science and also doing the research of doing, like, what I'm actually doing.
Coming to the pediatric cancer, as you know, Nebraska is the heartland of the U.S. A lot of the corn and soybean is produced here, but also Nebraska has a very high pediatric cancer incidence.
Ken Cook: Yes.
Jabeen Taiba: So compared to the U.S. average population. So that's what motivated me to study pediatric cancer. And my mentor, she is an expert who was working on waterborne chemicals, Dr. Elina Rogan. So she is a chemist, and she is known for her work in chemistry and carcinogenesis, DNA adducts.
So, you know, working under her guidance, and while I was working with her on these agrichemicals, there was a pesticide issue—pesticide contamination issue here while I was working on these. So that was about the contamination of neonicotinoids, which were like replacement of OPs from the seed coating, accumulation, and all that.
So while I was working on that, that paved a pathway to study pesticides further. And also pesticide mixtures is an important area of research. As a young grad student, NIH's interest to study the chemical mixtures—that's where my motivation came from actually to study the mixtures because my mentor's group was already working on individual chemicals.
They were looking at water contamination, like atrazine and nitrate, because that contamination is also high in Nebraska.
Ken Cook: Right. Yes.
And the University of Nebraska Medical Center is highly regarded for this kind of research, looking into the relationship between these kinds of exposures and health outcomes. So renowned. So you landed in the right place.
I just have to go back and say, so you started off as a dentist. And then you decided to make the leap to be an academic researcher. What was the motivation there? You just didn't want to keep drilling people's teeth? What caused you to make that leap? It's very interesting to me.
Jabeen Taiba: So it's more about, like, I want to do research on a larger scale, like more from just oral health to systemic health. That's what motivated me to do this further.
Ken Cook: Got it.
Okay, that makes a lot of sense. Instead of looking at just an X-ray of one person's teeth, you wanted to do epidemiological studies on much bigger issues. Got it, I got it.
So say a little bit about, from a scientist's perspective, say a little bit about the difficulty and the different ways people have tried to study mixtures. And we know from the CDC biomonitoring program, we know from any number of other studies that people—we find the mixtures in people already. So we know the exposures are happening.
Just like we found dozens of carcinogens, dozens of neurotoxins, dozens of chemicals that are known to affect our hormones, we found those in umbilical cord blood. So it starts before we come into the world.
But why is it so difficult? Talk through some of the complications of trying to understand and why it's so much relatively easier to study one chemical at a time, the laboratory work, the samples that are needed and so forth. It's just miles easier, challenging as it is, miles easier to do that than to even look at two or three substances, right? All the variations you'd have to look at. Can you say a little bit about that?
Jabeen Taiba: Sure. When we are doing biomarker studies, as you brought up the CDC's biomonitoring program, yes, that's a wonderful program. They have measured so many different chemicals, but very—some pesticides were measured, but we don't have very consistent information.
I mean, from my perspective, one reason I could think of is, you know, when compared to PFAS or PBDEs, some of these chemicals, like pesticides, their biotransformation is much faster. Like sometimes, you know, it's hard to measure them because of their half-lives, a short half-life.
Ken Cook: In the body. You eliminate them pretty quickly. Yeah.
Jabeen Taiba: In the body. Yes. So that could be one of the challenging things. And also, to measure pesticides in biological samples, again, it's cost. It's not cost-effective.
Ken Cook: Also challenging.
Yeah.
Jabeen Taiba: I mean, there are so many studies that have already done mixtures using different chemicals and different outcomes, like neurological outcomes or other hormone or other health outcomes. But not a lot has been done in cancer, but that's, I think, a more upcoming area.
Even our own research group, we are pursuing further by considering biomonitoring or even using the prenatal, you know, the fetal blood spots or that kind of—our group is trying to explore those and measuring the pesticides in another way, using wristbands. So that's some areas that we are trying.
Yeah, usually the challenge is, you know, their biotransformation and measuring them in biological samples is something that, from my perspective, I find somewhat challenging.
For example, like atrazine or, you know, biotransforms very fast. Like, if you measure in urine or blood serum, you know, we might not find the level.
Ken Cook: Oh my gosh, yeah.
It might be gone already. It might be, yeah, already eliminated in the waste stream. And so then the question is, well, did it have any effect before it was eliminated? And it's hard to pinpoint that.
And also, if only we were worried about exposures to pesticides in Nebraska and other agricultural-dominant areas, but there's all the other things we're exposed to as well that might have similar health endpoints. And by health endpoints, I mean like cancer or some sort of neurological problem.
And so to take on something like this, to me, what's so important about it is that the potential impact of mixtures was not a consideration for bringing these materials to market, getting them into commerce and having them end up in people.
None of those scientific mysteries were explored before the introduction, and they end up not just in the environment, our air, our water, our food, but in us.
Let's take the two sort of general categories of data that you looked at, Jabeen, in this study. So first you looked at the, I guess, the exposure factor, which is the U.S. Geological Survey's data collection on pesticide use, right?
Can you say a little bit about that data set? Because we don't—you know, in California, I'm in California, talking to you from California, we have really robust pesticide record-keeping data here in the state. And we have used that actually to do some studies of our own looking at chemical mixtures.
But the rest of the country, not so much. So say a little bit about this data set, what its strengths are, and some of its shortcomings.
Jabeen Taiba: Sure. Yes, I think U.S. Geological Survey's Pesticide National Synthesis Project, that's like a wonderful publicly available data set. You can just download it for a free of cost.
And that data set, it has about 500 active ingredients of these pesticides that are applied on U.S. crop plants on a county scale, actually. So if someone is considering to study on a county scale and if they're interested in a larger geographical population like the U.S., it's a very nice source of data, I would say.
The drawback is currently the data is only available until 2019.
Ken Cook: Right.
Jabeen Taiba: I think going previously it was released annually, but I think now they have made some changes to that.
And yeah, this data set is more for someone who is doing an ecological study, but it's not—
Ken Cook: Yes.
Jabeen Taiba: It's not very granular because exposure differs between county level to the census tract and census block, and it differs. So if someone is really interested to study that, that's one of the drawbacks of that. But still, yes, fine detailed enough.
Ken Cook: Yeah, it's not fine detail, not detailed enough to go super local.
Jabeen Taiba: Yeah, but still it's a good resource, I would say. They have two different types. One is just based upon the crop plant. That's the data that I have used for my study, but they also have another type of data available that is based upon six different types of crops and the pesticides that have been applied. It's for a different purpose.
So yes, if someone is looking on a large scale, I would still recommend using that data set, actually.
Ken Cook: Yeah, and it's pretty much all we have. I mean, you know, on the agricultural pesticide front, which, you know, just—it's been a theme of some of the podcasts I've done with other researchers—that we start off needing more data.
And if there are steps that are being taken that reduce what's available, that's really, no matter what the field, that's concerning, because that means we don't have the ability to look at some of these basic questions without the underlying data.
And so obviously there's, from some corners of the social sphere, people don't want that data out there. And so I think there's interest in continuing to fund that function at the government level.
And then let's look at how—okay, so you got the data on pesticide usage from USGS. So what was the next step to look at the relationship between that and various pediatric cancer outcomes? What did you have to do?
Jabeen Taiba: Yes. So this, as I told you, this data set has about 500 types of active pesticide ingredients. So, yes, yes. It's for all over the U.S., actually. It's for all over.
Ken Cook: Let's make note of that. 500, right? Just in Nebraska. 500. Yeah, yeah.
Jabeen Taiba: But I'm talking about Nebraska. Yeah. You have information for about that much information, but my goal was to select some top pesticides, you know, that were consistently applied across my study time, for example, over a period of like 22 years.
Ken Cook: Mm-hmm. Yeah.
Jabeen Taiba: You know, I wanted to make sure these pesticides have been applied every year and also these were applied across the 93 Nebraska counties.
So that was the criteria that I developed to select the top chemicals. So based upon this criteria that, you know, they have been—they have to be applied at least across 90% of my timeline, which is they have to be applied at least 20 years of the study period.
Ken Cook: Yeah, so you have a lengthy period of time during which a lot of babies would have been born in those counties, I presume, and sparse as some of the populations are in those counties, but you would have a substantial population, and you want to look over multiple years.
Let me ask you, when you started off selecting the pesticides, did you select pesticides that had shown in lab studies or else other ways that they were carcinogenic, or did you just look at all of them?
Jabeen Taiba: No, I just looked at all of them because my study was not from a toxicological perspective. It was more from an ecological and a mixtures perspective.
My criteria was they have to be applied consistently across the timeline and in all the Nebraska counties. So based on that, I identified 32 pesticides.
Ken Cook: Weeds killers, yeah.
Jabeen Taiba: That were consistently applied for this longer period, and these were like herbicides are dominant and followed by insecticides.
Ken Cook: Yeah, yeah, yeah. And so when you looked at that, what kind of—then you looked at a whole series of factors. You looked at race, looked at income, employment, access to care, which I thought was a really interesting element.
If you have any more to say about the access-to-care piece, because that seems so important in determining diagnoses. If someone goes to the doctor more often, there's a greater likelihood they'll be diagnosed with something if it's a miss. So where did those data come from?
Jabeen Taiba: So those data actually, I would call it social vulnerability. Yes, that came from the U.S. Census Bureau. And that is, again, publicly available data.
So I got that for these different domains that we were just talking about: race, income, education, access to care. So that's where that data came from. And we also got the pediatric population for each county as well from that Census Bureau data, actually.
And I did not really look into individual factors, but, you know, that's—we have adjusted for those covariates in our model, actually.
Ken Cook: So you had to build a model which I'm gonna read it out because my audience probably won't—I'm not sure I understand it even reading it. "Generalized weighted quantile sum regression model." Wow, that's a mouthful. Tell me what happens inside that model.
Jabeen Taiba: Sure. Thank you for asking. Yes, this has been one of my favorite—
Ken Cook: I can tell you're excited. The nerd in you is really popping right now on the screen, Jabeen. I think we've hit pay dirt here. Go on.
Jabeen Taiba: So this is one of the very advanced mixture models. There are different types of mixtures models, and depending upon your research question, you can choose the model.
So this GWQS—we call it GWQS, this weighted quantile sum regression model—what this model does is it not only helps us to understand the overall effect of that chemical mixture, but it also helps us to identify the potential chemicals that would have caused that joint association.
Ken Cook: The ones that are driving the estimates, yeah, the outcomes, yeah.
Jabeen Taiba: Yes. So that's why this model is very helpful for that. And what it does is when you include all the chemicals, like how many ever chemicals you include, so what it does is into the—
Ken Cook: So you dump the chemicals into the model and the model already has all the characteristics of the pediatric health outcomes and the social demographic factors.
Jabeen Taiba: Yes.
So what it does is it creates an index of all these chemicals. So that's the first step, how this model works. And then, depending upon your outcome, like whichever cancer outcome you're selecting, it would look at the association.
In the second step, you know, it would look at the association between that weighted index and that specific cancer type while adjusting for some of the covariates that we talked about—the race, income, and all that.
So that's what it does. Because all our data, the cancer cases, it's like a number. It's count data. This model, what it does is it divides those cancer cases by offsetting it with the pediatric population for that specific county. So it gives us a rate, actually, of what would be the rate of the mixture of this whole pesticide mixture for that specific cancer type.
Ken Cook: Yeah.
So this is a—as I, I'm not saying I'm a master of the literature, but because I have toxicologists on my staff who've wrestled with mixtures questions before, and I'll make sure to send you their papers if you're not aware of them.
But, you know, this is really pioneering work. I'm really excited about it.
So how did you—how does the model figure out the association by cancer type? And you mentioned in the paper that it's slightly stronger for cancers of the brain, pediatric cancers of the brain—I can't even, I don't even want to think about it—and also the central nervous system, CNS cancers.
How does the model help you figure out and focus on the specific cancers?
Jabeen Taiba: So this model, what it does is when you're looking for each specific cancer type, you know, there are several cancer types that I would include in the model.
So for each cancer type this model looks at those associations, and it gives us a beta and a 95% confidence interval. So for each it gives that.
So based upon those estimates, like we identify which cancer had that slightly higher association compared to the other cancer types. So we run this model for every cancer type, actually. And then that's how, based upon those estimates, we identify which is higher.
Ken Cook: Yeah, which ones are elevated, yeah, relatively elevated.
And then you're also able to identify the specific pesticides. The top three are weed killers: dicamba, glyphosate, and paraquat. I think some of them are—trisulfuron is an insecticide, I think. That's a weed killer too? Okay, yeah, that's right. Of course, that makes sense.
Jabeen Taiba: Yes. Yeah, trisulfuron. Yes, it's a herbicide. It's a sulfonylurea. Yeah.
Ken Cook: So when you stand back and look at it, what questions come to your mind that we should be thinking about in the real world?
This is a model. I'm sure, I know your paper is fastidious in talking about its limitations. So I'm very, very aware of that and I don't want to overstate beyond what your model claims either.
But still, now that you've done the work and you've seen these associations specific for brain cancer and cancers of the central nervous system compared to overall cancer and leukemia or blood cancers, what do you say about how we should be thinking about this?
And I mean, what we've been telling people for a long time is we really shouldn't just accept that it's a mystery what mixtures might be doing. We should be exploring what they might be doing and then ask ourselves: Is our policy system, is our regulatory system, is the way these things are used in the real world, are we really taking account of mixture effects?
And should we take steps to avoid some of these exposures if that's—if we're not gonna figure out the risk to three decimal points, which is hard—what does this tell us about how we might want to change the regulatory system or change behavior?
If you were talking to a farmer, talking to a farm family with a farm wife, how do you approach that question?
Jabeen Taiba: Yes.
That's a very good question, Ken. I mean, yes, these results could be still data-driven. Like, you know, we are talking from an ecological standpoint. I haven't measured—like, these are not coming from a biom—I'm not talking that exposure to these chemicals is causing this because I'm talking about the—yeah, it's just anonitoring standpoint or something, but still, I would still consider and value these results.
But still, we can't say—I'm not talking that exposure to these chemicals is causing this because I'm talking about the—yeah, it's just an association. I'm not talking about the biological pathways or causality of the associations.
However, I would still—any kind of environmental If it—come, we've talked about this. I talked about it at length with Philippe Grandjean, who exposure, be it a larger dose or a smaller dose, because dose is not the important thing, right?
Ken Cook: Yeah.
Jabeen Taiba: Even the smaller exposure could cause a larger effect. So yes.
Ken Cook: If it—come, we've talked about this. I talked about it at length with Philippe Grandjean, who wrote a great paper on the dose-makes-the-poison notion.
And it turns out that the timing of the exposure, in this case an infant developing in the womb or an infant just—a baby that's just been born, more vulnerable, the timing, the fact that the receptor—the receiver of the dose—is a smaller person, all these considerations, and then sometimes certain types of cancers we have reason to believe might be more susceptible to being triggered by mixtures.
So it's all of those things, right? So it argues for caution, I think.
Jabeen Taiba: Yes, it argues for caution. If I am to talk to a farmer's family or someone working in ag, I would still tell them to be cautious, to use all the personal protective equipment possible.
And yes, because we are talking about the critical windows of exposure, you know, that's very important, right? For any disease, not only for cancer, critical windows of exposure, because exposures happen before birth.
Ken Cook: Yeah.
Jabeen Taiba: Like it's happening before prenatal exposure. So yes, it's always safe to be cautious about any chemical.
Ken Cook: Yes.
Yeah, and you know, if you're in farm country, it might be in your drinking water, might be in air, drifting from fields.
You know, I've spent a lot of time on farms, grew up on my uncle's farms, went to graduate school at University of Missouri in soil science. One of my professors on my master's committee was studying we're going to rely more on chemicals, which we've done over time, as particularly weed killers to eliminate the need for tillage field work to make it no-till farming. This was in the 1970s, so going back a ways.
And of course, the whole question was if we're going to rely more on chemicals, which we've done over time, as particularly weed killers to eliminate the need for tillage field work to make it more efficient and faster.
One farmer on a big piece of equipment—a spray rig and planter rig combined—can cover a lot more acreage than a concern, and there's, you know, even with the MAHA Commission, the first report that came out, they referenced mixtures, 30 years ago, when they had to go in and prepare the seedbed in much more granular, literally granular detail.
So it is a concern, and there's, you know, even with the MAHA Commission, the first report that came out, they referenced mixtures, suggested that they needed to look at that.
There's been considerable resistance to looking at mixtures, just if we're on—if we have to go into anything political or controversial.
I haven't seen any pesticide companies come forth and sort of openly say, "Hey, maybe we should look at mixtures of chemicals that are produced by my company and five other companies and see what that might mean." That's not a conversation I've ever heard the industry suggest should be started.
And so, you know, there's inherently, looking at these exposures in relation to any health outcome, there's going to be controversy, and you're in Nebraska. So I'm just really grateful that you developed this initial study.
So let me ask you, what is next? Are you gonna be following up on this? And specifically, I was wondering if this same methodology, it seemed to me it could be related to other types of health risks—neurodevelopmental disorders, for example, or endocrine disruption, whatever.
It seems like the model would be suitable to that. But what's your next big thing, Jabeen?
Jabeen Taiba: Yes.
So why not expect that? Yes, I'm interested in mixtures. It's like I'm very passionate about working on mixtures.
Ken Cook: Yes, stick with the mixtures, go, you go.
Jabeen Taiba: So I am currently studying endocrine-disrupting chemicals, and that's about female reproductive outcomes. So that's my next area.
In addition to the pediatric environmental health, I am expanding to female reproductive health. So that's my—
Ken Cook: Oh, fantastic. Well, congratulations. I can't wait to see what you come up with next.
And thank you for spending some time with us and diving into the details of your really exciting and important study. I'm thrilled to have had a chance to talk to you.
And I just wanted to ask you, we were involved in something that was called the Halifax Project. I don't know if that's crossed your radar, but there was a study done looking at—actually it was a business professor at the University of Halifax.
And he had a family member, a beloved family member, die of cancer, so he started reading cancer biology. And he's, you know, an autodidact—and when I mentioned that to him one time, he said yes, and I had to look up what that meant. I had to teach myself what autodidact meant.
He came up with this notion, looking at the Hallmarks of Cancer paper, the famous paper, that maybe there were some chemicals that were acting on some hallmarks of cancer but weren't complete carcinogens in the way that we categorize them.
So that they might trigger one or the other of the pathways that maybe affected cell immortality or angiogenesis or some other—one of the other hallmarks. And that hallmark list has grown over time from the original paper from Weinberg and Hanahan.
But what do you make of that? We actually co-sponsored a symposium at NIEHS when Linda Birnbaum was running it on chemical mixtures. And we brought scientists from this Halifax Project. He sent a note out to oncologists all over the country and asked them what they thought about this idea.
And hundreds of them wrote back and said, "We want to contribute." So they did two sets of papers, one on chemicals that might affect some aspects to trigger cancer by affecting some of the hallmark mechanisms, and then another set of papers suggesting what types of phytochemicals might suppress some of these hallmark mechanisms.
And so two journals devoted their entire issues to these papers that started with a guy who was a business professor and lost a beloved family member to cancer.
But had you come across that? We don't have to include this in the podcast, but I'm just curious to know if you came across that mixtures study or seminar.
Jabeen Taiba: I haven't read—I mean, I have heard about it, but I haven't really looked into it. But I think now you mentioned—you went into details about it. I think it's very interesting. I would look into that. Yeah.
Ken Cook: I'll send it all along to you because—and we sort of got involved because the study authors contacted us and said, "What can we do?"
And so my first call was to Linda Birnbaum when she was running NIEHS, and she wrote back right away and said, "Let's do a symposium on mixtures."
And we had luminaries, cancer scientists, oncologists coming to participate, so I'll make sure to send that along to you. I think you'll find it really stimulating.
Thank you again. Thank you again. I'm so excited. I can't wait to see what you're doing next with your career and to think it all started with dentistry. I love that. I love that your horizons expanded so broadly and that you decided that you were gonna take on some really big questions.
Nothing wrong with being a dentist.
Jabeen Taiba: Nothing wrong with that at all.
Ken Cook: I want to be clear, nothing wrong with that at all. I'm going to see my dentist in about 10 days, just in case she's watching.
Thanks again, doctor.
Jabeen Taiba: Thank you.